The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
In contrast, phosphate is actively produced by a combination of secretion of phosphate-containing compounds, including ATP, and by phosphatases that cleave phosphate to create a high phosphate concentration at the mineralization front. Alkaline phosphatase is a membrane-anchored protein that is a characteristic marker expressed in large amounts at the apical (secretory) face of active osteoblasts.
252Cf(12C,αxn)260−xNo (x=3?) This reaction was studied at the LBNL in 1961 as part of their search for element 104. They detected 8.2 MeV alpha particles with a half-life of 15 s. This activity was assigned to a Z=102 isotope. Later work suggests an assignment to 257No, resulting most likely from the α3n channel with the 252Cf component of the californium target.
==== Indigenous Americans ==== Aztec paintings, Central American temples, and the great burial mounds in the Southern United States are frequently adorned with depictions of rattlesnakes, often within the symbols and emblems of the most powerful deities. The Feathered Serpent of Mesoamerican religion was depicted as having the combined features of the quetzal and rattlesnake. The Ancient Maya considered the rattlesnake to be a "vision serpent" that acted as a conduit to the "otherworld". Rattlesnakes are a key element in Aztec mythology and were widely represented in Aztec art, including sculptures, jewelry, and architectural elements.
Sources: en.wikipedia.org
== Pharmacology == In 2011, the Bohn lab noted antinociception against both chemically induced and inflammation-derived pain, and experiments indicated lack of opioid receptor modulation, but were unable to define a particular target. A 2019 study by a cross-site Australian and U.S. group discovered through cultured neuronal networks that conolidine may inhibit the Ca v2.2 channel, a mechanism seen in molecules like conotoxin. The group was unable to rule out partial polypharmacology against other targets.
=== Antiestrogenic effects === Progesterone, like all progestogens, has antiestrogenic effects in certain tissues such as the uterus, cervix, vagina, and breasts, and possibly also the brain. These effects are mediated by activation of the PR in these tissues. Progesterone does not have antiestrogenic effects in the more conventional sense of binding to and antagonizing the ER or binding to and inhibiting enzymes involved in estrogen biosynthesis. Instead, for instance in the endometrium, progesterone causes downregulation of the ER and upregulation of the estrogen-inactivating enzymes 17β-hydroxysteroid dehydrogenase 2 (converts estradiol into estrone) and estrone sulfotransferase (converts estrone into estrone sulfate). The antiestrogenic effects of progesterone and other progestogens form the basis for their only approved indication in menopausal hormone therapy: prevention of long-term unopposed estrogen-induced endometrial hyperplasia and increased endometrial cancer risk in women with intact uteruses. In the breasts, progesterone and other progestogens downregulate the ER as well as the estrogen-activating enzymes steroid sulfatase (converts estrone sulfate into estrone) and 17β-hydroxysteroid-dehydrogenase 1 (converts estrone into estradiol) and upregulates estrone sulfotransferase. However, other studies suggest that progestogens do not downregulate ER expression in the breasts. When applied directly to the breasts in women, progesterone can block the proliferative effects of estradiol.
Endocrine glands derive from all three germ layers. The natural decrease in function of the female's ovaries during late middle age results in menopause. The efficiency of all endocrine glands seems to decrease gradually as ageing occurs. This leads to a generalized increase in the incidence of diabetes mellitus and a lower metabolic rate.
Sources: en.wikipedia.org
=== Recurring === Eme Ikwuakor as Elijah, an attorney at Jacobson Moore who was in a romantic relationship with Olympia Beau Bridges as Howard "Senior" Markston, a managing partner at Jacobson Moore, father of Julian, and soon-to-be ex-father-in-law of Olympia. He guardedly supports Olympia's career and efforts to develop a new revenue stream for the firm, telling her how he believes being father-in-law is a forever role. Patricia Belcher as Mrs. B, an administrative manager at Jacobson Moore. It is later revealed her full name is Emmalyn Belvin. Yael Grobglas as Shae Banfield, a jury consultant at Jacobson Moore Piper Curda as Kira, a woman who works at the information technology (IT) department at Jacobson Moore who begins a relationship with Sarah Marnee Carpenter as Ellie Kingston, Matty and Edwin's deceased daughter and Alfie's mother, who appears in flashbacks Andrea Londo as Simone, a recently hired junior associate at Jacobson Moore who attended the same law school as Sarah Niko Nicotera as Joseph "Joey" Danza, Alfie's father who is a drug addict Justina Machado as Eva (season 2), Senior's fourth ex-wife who is also a lawyer and member of the executive committee at Jacobson Moore James Lesure as Lester "The Wolf" Logan (season 2) Justin Cornwell as Mr. Hodges (season 2), Olympia's love interest who is also a lawyer Sarah Wright Olsen as Gwen (season 2), a productivity consultant evaluating Jacobson Moore Henry Haber as Hunter (season 2), an eager new associate on Olympia's team
The gallbladder is a hollow pear-shaped organ located posterior to the inferior middle part of the right lobe of the liver. It is variable in shape and size. It stores bile before it is released into the small intestine via the common bile duct to help with digestion of fats. It receives bile from the liver via the cystic duct, which connects to the common hepatic duct to form the common bile duct. The gallbladder gets its blood supply from the cystic artery, which in most people, emerges from the right hepatic artery. Gallstone is a common disease in which one or more stones form in the gallbladder or biliary tract. Most people are asymptomatic but if a stone blocks the biliary tract, it causes a gallbladder attack; symptoms may include sudden pain in the upper right abdomen or center of the abdomen. Nausea and vomiting may also occur. Typical treatment is removal of the gallbladder through a procedure called a cholecystectomy. Having gallstones is a risk factor for gallbladder cancer, which, although quite uncommon, is rapidly fatal if not diagnosed early.
=== Generic names === Buserelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while buserelin acetate is its USANTooltip United States Adopted Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name, buséréline is its DCFTooltip Dénomination Commune Française, and buserelina is its DCITTooltip Denominazione Comune Italiana. While under development by Hoechst AG, buserelin was also known as HOE-766.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.